Dynamics of growth differentiation factor 15 in acute heart failure.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2021
Historique:
revised: 21 03 2021
received: 09 01 2021
accepted: 08 04 2021
pubmed: 4 5 2021
medline: 29 10 2021
entrez: 3 5 2021
Statut: ppublish

Résumé

Risk stratification in acute heart failure (HF) patients can help to decide therapies and time for discharge. The potential of growth differentiation factor 15 (GDF-15) in HF has been previously shown. We aimed to study the importance of GDF-15-level variations in acute HF patients. We retrospectively evaluated a cohort of patients hospitalized due to acute HF. GDF-15 was measured both at admission and on the discharge day. Patients were followed-up during a 3 year period. The endpoint under analysis was all-cause mortality. GDF-15 variation is equal to [(admission GDF-15 - discharge GDF-15)∕admission GDF-15] × 100. Variation was categorized in levels of increase or decrease of GDF-15. Patients were cross-classified according to admission and discharge GDF-15 cut-off points. A Cox regression analysis was used to assess the prognostic impact of GDF-15 variation and the impact of both admission and discharge GDF-15 according to the cross-classification. We studied a group of 249 patients with high co-morbidity burden. Eighty-one patients died at 1 year and 147 within 3 years. There was a modest decrease in GDF-15 during hospitalization from a median value of 4087 to 3671 ng/mL (P = 0.02). No association existed between GDF-15 variation and mortality. In multivariate analysis, patients with admission GDF-15 ≥ 3500 ng/mL and discharge GDF-15 ≥ 3000 ng/mL had a significantly higher 1 year death risk when compared with the remaining-hazard ratio = 2.59 (95% confidence interval: 1.41-4.76)-and a 3 year 1.76 (95% confidence interval: 1.08-2.87) higher death risk compared with those with both values below the cut-off. Growth differentiation factor 15 decreased during an acute HF hospitalization, but its variation had no prognostic implications. The knowledge of both admission and discharge GDF-15 added meaningful information to patients' risk stratification.

Identifiants

pubmed: 33938154
doi: 10.1002/ehf2.13377
pmc: PMC8318469
doi:

Substances chimiques

Biomarkers 0
GDF15 protein, human 0
Growth Differentiation Factor 15 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2527-2534

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

ESC Heart Fail. 2020 Apr;7(2):503-511
pubmed: 31951323
Eur Heart J. 2009 Oct;30(19):2346-53
pubmed: 19561023
JACC Heart Fail. 2017 Apr;5(4):287-296
pubmed: 28189578
Eur Heart J. 2009 May;30(9):1057-65
pubmed: 19168526
Circulation. 2010 Oct 5;122(14):1387-95
pubmed: 20855664
Heart. 2016 Dec 15;102(24):1963-1968
pubmed: 27456261
Cytokine Growth Factor Rev. 2013 Aug;24(4):373-84
pubmed: 23787157
ESC Heart Fail. 2021 Aug;8(4):2527-2534
pubmed: 33938154
Curr Heart Fail Rep. 2020 Feb;17(1):9-19
pubmed: 31916187
J Am Soc Nephrol. 2017 Jul;28(7):2233-2240
pubmed: 28159780
Eur Heart J. 2019 Oct 21;40(40):3345-3352
pubmed: 31093657
JACC Heart Fail. 2015 Jan;3(1):30-39
pubmed: 25447345
ESC Heart Fail. 2020 Oct;7(5):2230-2239
pubmed: 32649062
Eur Heart J. 2008 Oct;29(19):2388-442
pubmed: 18799522
Am J Cardiol. 2011 Oct 1;108(7):955-8
pubmed: 21784389
JACC Heart Fail. 2017 Oct;5(10):724-734
pubmed: 28958347
Can J Cardiol. 2014 Mar;30(3):312-9
pubmed: 24565256
Eur J Heart Fail. 2015 Nov;17(11):1133-43
pubmed: 26333529
Clin Chem. 2017 Jan;63(1):140-151
pubmed: 28062617
Chin Med J (Engl). 2019 Oct 5;132(19):2278-2285
pubmed: 31567379
Int J Cardiol. 2018 Mar 1;254:215-221
pubmed: 29407093
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):203-10
pubmed: 20966402
Dis Markers. 2017;2017:5271203
pubmed: 29180833
Eur J Heart Fail. 2012 Nov;14(11):1249-56
pubmed: 22843564
Clin Res Cardiol. 2015 Jun;104(6):491-9
pubmed: 25586507
Expert Rev Cardiovasc Ther. 2017 Oct;15(10):729-741
pubmed: 28830266
Eur J Heart Fail. 2018 Dec;20(12):1701-1709
pubmed: 30204280
Int J Cardiol. 2013 Oct 3;168(3):2186-94
pubmed: 23538053
J Am Coll Cardiol. 2007 Sep 11;50(11):1054-60
pubmed: 17825714
Eur J Heart Fail. 2016 Jan;18(1):81-8
pubmed: 26497848
Clin Chem. 2007 Feb;53(2):284-91
pubmed: 17185363
Clin Chem. 2016 Dec;62(12):1612-1620
pubmed: 27756762
Crit Care. 2015 Nov 10;19:399
pubmed: 26556500
ESC Heart Fail. 2018 Dec;5(6):1017-1022
pubmed: 30144302

Auteurs

Patrícia Lourenço (P)

Internal Medicine Department, Centro Hospitalar Universitário São João, Porto, Portugal.
Heart Failure Clinic of the Internal Medicine Department, Centro Hospitalar Universitário São João, Porto, Portugal.
Cardiovascular R&D Unit (UnIC), University of Porto, Porto, Portugal.
Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, Porto, 4200-319, Portugal.

Filipe M Cunha (FM)

Endocrinology Department, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.

João Ferreira-Coimbra (J)

Internal Medicine Department, Centro Hospitalar Universitário São João, Porto, Portugal.

Isaac Barroso (I)

EPIUnit-Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Serviço de Medicina Interna, Hospital CUF Porto, Porto, Portugal.

João-Tiago Guimarães (JT)

Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, Porto, 4200-319, Portugal.
Clinical Pathology Department, Centro Hospitalar Universitário São João, Porto, Portugal.

Paulo Bettencourt (P)

Cardiovascular R&D Unit (UnIC), University of Porto, Porto, Portugal.
Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, Porto, 4200-319, Portugal.
Serviço de Medicina Interna, Hospital CUF Porto, Porto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH